Evidence map›Paper›PMID 40834247›Full record

ArticleDiabetes care2025

Comment on Griffin et al. Use of SGLT2i Versus DPP-4i as an Add-on Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes. Diabetes Care 2025;48:361-370.

Sayna Bagheri, Simeon I Taylor

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sayna BagheriDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD.
Simeon I TaylorDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD.ORCID 0000-0001-7500-7854

Funding

Genetics of Response to CanagliflozinR01DK118942 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI BEITELSHEES, AMBER L, TAYLOR, SIMEON I. · 2018 to 2022
$3.5M
Pharmacogenetics of the Response to a GLP1R AgonistR01DK130238 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI AMBER L BEITELSHEES, SIMEON I. TAYLOR · 2022 to 2026
$3.3M
Probing an Unexplored Intracellular Pathway in Diabetes PathogenesisR01DK131173 · NIDDK · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI PRENDERGAST, GEORGE C, REICHMAN, MELVIN · 2022 to 2024
$1.7M
Division of Diabetes, Endocrinology, and Metabolic Diseases R01DK118942NIDDK NIH HHS R01 DK118942NIDDK NIH HHS R01 DK130238NIDDK NIH HHS R01 DK131173
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40834247
PMCPMC12368376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.